What the evidence says about Avance® Solo

Huang et al[1]

Prospective non-comparative real-world clinical investigation involving 101 patients undergoing revision total knee/total hip arthroplasty across 7 sites.

Findings:

97% of participants experienced **no SSCs** at 30 days post-operatively

99% of assessments rated peri-wound skin as '**healthy**'

Svensson-Henriksson[2]

Simulated clinical use tests compared to two canister-less NPWT systems.

Findings:

Avance® Solo offers **consistent negative pressure**, even with exudate.



Extend Your Excellence

Mölnlycke Incision Care Solutions support you in applying the same scientific rigour to the incision care as the surgery.

Step-up approach:
Avance® Solo
High-risk patients need the extra protection of closed incision negative pressure therapy

Baseline:
Mepilex® Border Post-Op
Every patient deserves an advanced post-operative dressing

Foundation:
Granudacyn®
Set up the body to heal with surgical irrigation

Ensure your use of Avance® Solo is clinically appropriate and cost-effective

The Mölnlycke Simplified Surgical Site Event Risk Assessment Model supports surgeons in identifying patients most likely to benefit from Avance® Solo.

- Standardised approach to assessing each patient's risk of post-surgical complications.[7]
- Supports sound clinical judgement to deliver the most clinically suitable, economically responsible choice for each patient.[7]

Avance Solo assortment

Incisional negative pressure therapy kits	
8881020	Avance Solo Pump, Canister and 10x20cm Border Dressing
8881030	Avance Solo Pump, Canister and 10x30cm Border Dressing
8881035	Avance Solo Pump, Canister and 10x35cm Border Dressing
8880050	Avance Solo Pump and Canister
Additional dressings (packs of 2)	
881020	10x20cm Border Dressing
881030	10x30cm Border Dressing
881035	10x35cm Border Dressing
Canister	
880050	50ml Canister

References: 1. Huang P. et al. Optimizing post-operative outcomes: evidence supporting Avance® Solo negative pressure wound therapy following revision hip and knee arthroplasty procedures in the US. Poster presentation at the EWMA congress, 2026. **2.** Anette Svensson Henriksson. Single use negative pressure wound therapy (suNPWT) system with controlled fluid management technology — an evaluation of performance. Wounds International 2021 | Vol 12 Issue 4 |. **3.** Hannah Groenen et al. Incisional negative pressure wound therapy for the prevention of surgical site infection: an up-to-date meta-analysis and trial sequential analysis. www.thelancet.com Vol 62 August, 2023 **4.** Anette Svensson Henriksson, Alit Putra, Anna Grou. Computational modelling of impact of three negative pressure wound therapy systems in supporting the healing of surgical incisions: a finite element simulation study. SAWC Spring | WHS 2026, April 8–12, Charlotte USA. **5.** Kilpadi DV, et al. Evaluation of closed incision management with negative pressure wound therapy (CIM): Hematoma/seroma and involvement of the lymphatic system. Wound Repair Regen. 2011;19(5):588–596. **6.** Loveluck J, et al. Biomechanical Modelling of the Forces Applied to Closed Incisions During Single-Use Negative Pressure Wound Therapy. EPlasty. 2016;16:183–195. **7.** SSERA Group (2023) Surgical patient population risk assessment: The simplified SSERA assessment model. Wounds International, London. Available to download from www.woundsinternational.com

Find out more at www.molnlycke.com

Mölnlycke®



Avance® Solo

Surgical incision care without compromise for high-risk patients

Extend Your Excellence

Mölnlycke®

The consequences of surgical site complications (SSCs) and delayed healing can be devastating.

Up to **6 out of 10** orthopaedic patients risk developing post-operative blisters[1]

11 extra days in hospital due to SSI[2]

CiNPWT is well documented – through clinical experience and evidence – to help reduce surgical site complications.[3]

The development of Avance® Solo is driven by three core principles:

1
Employing a dressing that forms a **secure, gentle and protective seal** to protect the wound, manage drainage, and distribute forces evenly across the incision.[2,4]

2
Applying **optimised, controlled negative pressure** to support dressing performance, reduce incision line tension, and provide controlled peri-wound compression.[4–6]

3
Delivering maintained and consistent negative pressure therapy even in the presence of exudate.[2]

Protect your outcomes

Avance Solo is clinically shown to minimise risk of blistering

Using the same contact layer as Mepilex® Border Post-Op, Avance Solo helps minimise the risk of blistering thanks to Safetac® technology. Five clinical trials with 600+ patients show minimal to no skin damage in patients treated with Mepilex Border Post-Op or Avance Solo.

Extend Your Excellence with Avance® Solo

1
Secure, gentle and protective seal

Safetac is trusted and proven

More than 750 peer-reviewed studies, including 62 RCTS, confirm its performance advantages.

Safetac® TECHNOLOGY



2
Optimised, controlled negative pressure

3
Maintained and consistent therapy

The result:
consistent uninterrupted delivery of therapy at **-125mmHg** for up to 14 days, with a 7-day dressing wear time.